All In Biotech

Free tool

FAERS Monitor: Zituvio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211566 or its brand name (Zituvio, Sitagliptin). Reports on generic versions are filed under their own applications.

Reports

10,989

Serious

10,521

96% of reports

Hospitalization

6,430

Death reported

1,161

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • acute kidney injury913
  • diarrhoea621
  • nausea561
  • general physical health deterioration553
  • fatigue536
  • dyspnoea534
  • vomiting524
  • lactic acidosis495
  • drug interaction446
  • drug ineffective402
  • off label use390
  • anaemia389
  • hypoglycaemia382
  • dizziness373
  • fall340

Reports by year received

View as table
YearReports
20078
200826
200948
2010195
2011141
2012115
2013191
2014225
2015356
2016432
2017520
2018799
2019801
2020996
2021959
20221,025
2023874
20241,057
20251,201
20261,020

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,170 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lactic acidosisSignal49529.727.213,506
hypoglycaemiaSignal38215.213.85,020
acute kidney injurySignal91311.510.88,737
general physical health deteriorationSignal5539.28.54,029
drug interactionSignal4465.44.91,599
anaemiaSignal3893.93.5845
vomitingSignal5242.12.0322
fall3402.01.8160
diarrhoea6211.81.7246
dyspnoea5341.81.7196
dizziness3731.41.349
nausea5611.41.354
fatigue5361.31.242
off label use3900.90.810
drug ineffective4020.60.5127

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.